Jack Wall (Kildare South, Labour)
Link to this: Individually | In context

Question 679: To ask the Minister for Health his views on a submission (details supplied) regarding the availability of drugs for the treatment of M.S.; and if he will make a statement on the matter. [25563/12]

Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context

The manufacturer of Fingolimod (Gilenya®) has submitted an application to the HSE for the product to be reimbursed through community pharmacies under the High-Tech Drug Scheme. The list of medicinal products provided under the High-Tech Drug Scheme is reviewed on a regular basis. The application in respect of the product in question is currently under consideration. Tysabri must be administered in specialist centres under the supervision of experienced medical staff. This requires significant ancillary support including timely access to MRI, nursing support, educational guidance and ongoing follow up with the patient to ensure its safe and appropriate use. This presents challenges for hospitals and the HSE.

There is significant international discussion about the exact role of Tysabri and how to ensure the most appropriate safe, efficacious and cost effective use of this new technology in the treatment of Multiple Sclerosis patients. In the current climate, the increasing use of high cost medical technologies represent a significant challenge to the health system and society at large. The HSE is committed to ensuring that the maximum possible benefit is provided to patients from within the resources which the HSE has available to it.